Though the trial for patients with obesity and type 2 diabetes will come to an end, an obesity-only trial will continue.

Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due ...

Eli Lilly (NYSE:LLY) has decided to stop one of its obesity drug combination trials, pressing pause on a study that paired ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, ...

Fractyl Health (GUTS) announced on Friday that patients who stopped taking the GLP-1 class drug Tirzepatide and were treated ...

Millions of Americans who could benefit from GLP-1 weight-loss drugs are caught in the middle of a battle between drug ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...

The researchers found that, compared to the AGHE, the Mediterranean diet resulted in a significant decrease in waist ...

Elevance Health Inc. was hit with a proposed class action by a woman who says the insurer wrongly refuses to cover the weight-loss drug Zepbound for patients who need it to treat obstructive sleep ...

People with psoriasis might receive unexpected benefits from cutting-edge weight loss drugs like Ozempic and Zepbound, German ...

US pharma major Eli Lilly has halted a study of an experimental drug, bimagrumab, designed to prevent obesity patients from ...